Dáil debates

Wednesday, 16 June 2021

Ceisteanna - Questions

Covid-19 Pandemic

1:22 pm

Photo of Alan KellyAlan Kelly (Tipperary, Labour) | Oireachtas source

I will raise three issues. First, in relation to the Delta variant, I welcome what Mr. Paul Reid communicated in the HSE update yesterday. With regard to the AstraZeneca vaccine, an issue I have been raising for weeks, ongoing communication is needed and the commitment needs to be honoured by 19 July. Have studies been commissioned or has the Government received a briefing on the efficacy of the Johnson & Johnson vaccine against the Delta variant? That is an honest question. Does the Taoiseach have any information on this matter because I have not seen any and I follow it intensely? A Public Health England study, which only looked at AstraZeneca, found that the first dose is only 33% effective against the Delta variant. Another study this week showed that Pfizer and AstraZeneca are highly effective after two doses but there do not appear to be any studies on the Janssen vaccine from Johnson & Johnson. Will the Taoiseach ask the national immunisation advisory committee, NIAC, and National Public Health Emergency Team, NPHET, to look at this?

Second, the Irish Wheelchair Association has raised issues with regard to accessibility in cities and towns. There are good developments as regards outdoor dining and facilitating people but providing toilet facilities and access is a real issue.

Finally, I ask the Taoiseach to consider the provision of grants for community halls that have been closed due to Covid. While some groups have been funded - the Nenagh Musical Academy, for instance, received good funding for an outdoor performance - the halls in which many are based have no income. Once-off small grants to local authorities to allow them to keep these community halls with tenants going for the next six months would be appreciated. They are doing their best but their fixed costs are not being covered.

Comments

No comments

Log in or join to post a public comment.